New Dual-Action pill aims to tame type 2 diabetes
Disease control
Completed
This study tests an experimental drug, JP-2266, in adults with type 2 diabetes. The drug works by blocking two proteins (SGLT1 and SGLT2) to help lower blood sugar. Participants receive either JP-2266 or a placebo for 12 weeks, and researchers measure changes in HbA1c, a key bloo…
Phase: PHASE2 • Sponsor: Jeil Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC